搜索结果
靶点ID:TCMBANKGE000909
靶点别名:GLI; PAPA8; PPD1
靶点描述:GLI family zinc finger 1
染色体:12
染色体位置:12q13.3
靶点类型:protein-coding
HERB_ID:HBTAR001577
HGNC_Link:4317
OMIM_Link:165220
Ensembl_Link:ENSG00000111087
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
| TCMBANKHE003734 | radix tripterygii wilfordii | 雷公藤 | To expel wind-dampness, relieve swelling, alleviate pain and dredge the meridian passage./Rheumatoid arthritis, rheumatic arthritis, glomerulonephritis, nephropathy syndrome, erythematous lupus, dryness in eyes and mouth, Behcet’s syndrome, psoriasis, eczema, leprosy, scab sore, intractable lichen. | root, leaf and flower | |||
| TCMBANKHE003739 | Solanum nigrum L. | 龙葵 | Clove sore, swollen welling abscess, erysipelas, sprain from knocks and falls, mastitis, cervicitis, chronic bronchitis, chronic trachitis, acute nephritis, dysentery, infection of skin, leukorrhea, scant urine in children. | aerial parts |
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000039 | Zerumbone | zerumbone; NSC698299; zerumbone ; 2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; AIDS051828; 2,6,10-Cycloundecatrien-1-one, 2,6,9,9-tetramethyl-, (E,E,E)-; (E,E,E)-2,6,9,9-Tetramethyl-2,6,10-cycloundecatrien-1-one; 471-05-6; (2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; AIDS-051828; (2E,6E,10E)-2,6,9,9-tetramethyl-1-cycloundeca-2,6,10-trienone; 2,6,9 humulatriene-8-one | C15H22O | 218.33 | CC1=CCC(C=CC(=O)C(=CCC1)C)(C)C |
| TCMBANKIN036830 | triptonide | Triptolide, 14-deoxy-14-oxo-; AC-20331; 38647-11-9; KBio1_001608; Spectrum_001724; AKOS025401513; KBioSS_002204; BC216334; NSC165677; NCI60_001273; DivK1c_006664; Triptonide; KBio2_004772; SPBio_000614; Spectrum2_000477; KBio2_007340; Spectrum5_001806; ZINC100038923; SpecPlus_000568; KBio2_002204 | C20H22O6 | 358.385 | C12=C(C([H])([H])C([H])([H])[C@]3(C([H])([H])[H])[C@@]1([H])C([H])([H])[C@@]([H])(O4)[C@]45[C@]36[C@]([H])(O6)[C@]7([H])[C@@](C([H])(C([H])([H])[H])C([H])([H])[H])(O7)C5=O)C(=O)OC2([H])[H] |
| TCMBANKIN036834 | wogonoside | wogoninoglucuronide; N2501; wogonoside ; (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-5-(5-hydroxy-8-methoxy-4-oxo-2-phenylchromen-7-yl)-6-oxohexanoic acid; AC-20339; ZINC21992923; Y0212; BG01748878; AKOS015965557 | C22H20O12 | 476.387 | [C@]1([H])(O[H])[C@@]([H])(C(=O)O[H])O[C@@]([H])(Oc2c(OC([H])([H])[H])c(OC(c3c([H])c([H])c([H])c([H])c3[H])=C([H])C4=O)c4c(O[H])c2O[H])[C@]([H])(O[H])[C@@]1([H])O[H] |
| TCMBANKIN039335 | staurosporinone | C20H13N3O | 311.3 g/mol | C1C2=C3C4=CC=CC=C4NC3=C5C(=C2C(=O)N1)C6=CC=CC=C6N5 | |
| TCMBANKIN058205 | trans-resveratrol | (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene | C14H12O3 | 228.24 g/mol | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
| TCMBANKIN059452 | ethyl aldehyde | C2H4O | 44.05 g/mol | CC=O | |
| TCMBANKIN060111 | 17alpha-estradiol | C18H24O2 | 272.4 g/mol | CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O | |
| TCMBANKIN060429 | Cyclopamine | C27H41NO2 | 411.6 g/mol | CC1CC2C(C(C3(O2)CCC4C5CC=C6CC(CCC6(C5CC4=C3C)C)O)C)NC1 |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000018 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000061 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000064 | Digestive System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000078 | Neoplasms; Skin and Connective Tissue Diseases | Abnormality of the integument; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000092 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000294 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI000403 | - | Abnormality of limbs; Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI000891 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI001110 | Neoplasms | Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI001279 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases | Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI002512 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI002556 | Neoplasms; Musculoskeletal Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI002742 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | group | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003101 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003547 | - | Abnormality of limbs; Abnormality of the skeletal system | Acquired Abnormality | disease | |
| TCMBANKDI003879 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI004458 | - | Abnormality of the genitourinary system | Finding | phenotype | |
| TCMBANKDI004802 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI006121 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI006612 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI006861 | Neoplasms | Neoplasm; Abnormality of the musculature | Neoplastic Process | disease | |
| TCMBANKDI007110 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI007314 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI008266 | Stomatognathic Diseases | Abnormality of head or neck | Congenital Abnormality | disease | |
| TCMBANKDI009135 | Neoplasms | Neoplasm; Abnormality of the skeletal system | Neoplastic Process | disease | |
| TCMBANKDI009827 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Respiratory Tract Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases | Abnormality of head or neck | Congenital Abnormality | disease | |
| TCMBANKDI010214 | - | - | Neoplastic Process | disease | |
| TCMBANKDI010305 | Neoplasms | Neoplasm; Abnormality of the musculature | Neoplastic Process | disease | |
| TCMBANKDI011071 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome; Congenital Abnormality | disease | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011730 | Eye Diseases; Nervous System Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI011814 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI013615 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI014906 | Eye Diseases | Abnormality of the eye | Acquired Abnormality | disease | |
| TCMBANKDI015870 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI016026 | Neoplasms; Eye Diseases | Neoplasm; Abnormality of the eye | Neoplastic Process | disease | |
| TCMBANKDI016050 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI016118 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | group | |
| TCMBANKDI016890 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI016946 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017355 | - | Abnormality of the genitourinary system | Anatomical Abnormality | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI018481 | - | Abnormality of limbs; Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI019737 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI019879 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI020284 | Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020602 | Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI020860 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases | Abnormality of the digestive system | Congenital Abnormality | disease | |
| TCMBANKDI021455 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI022473 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI022646 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI024035 | Neoplasms | Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024870 | Pathological Conditions, Signs and Symptoms | Abnormality of the integument | Congenital Abnormality | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI028237 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI029520 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI029546 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Stomatognathic Diseases | Abnormality of head or neck | Congenital Abnormality | disease | |
| TCMBANKDI029922 | Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030041 | Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030204 | - | - | Neoplastic Process | disease | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI030653 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI030678 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031651 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI032062 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease |
滇IICP备16009434号-1 |
Dai SX Lab